Today we announced the first results of our collaboration with Ovation, demonstrating that genetic biomarkers can be used to: Identify strong and weak responders to GLP-1 therapies Quantitatively predict efficacy using BMI and HbA1c change Reveal over 2,500 genetic signatures across 1,100 genes Map 15 key biological mechanisms driving treatment response Our results shows how mechanism-based patient stratification can move GLP-1 prescribing beyond trial-and-error toward predictive precision medicine
Tirzepatide Tirzepatide, the active ingredient in the brand-name injectable GLP-1 medications Mounjaro and Zepbound, starts at 2.5 mg weekly and can be increased to 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg
Furthermore, since the alkane chain of DDA should be the origin of the hydrophobic character of alkylamine-GSH AuNCs, we studied the hydrophobication and phase transfer of GSH-AuNCs using alkylamines with various chain length (C4, C10, C12, C16 and C18) from water to dichloromethane
Damage caused by free radicals is known as oxidation or oxidative stress
GLP-1 Receptor Agonist Discontinuation Among Patients With Obesity and/or Type 2 Diabetes
Li IH, Ma KH, Weng SJ, Huang SS, Liang CM, Huang YS (2014) Autophagy activation is involved in 3,4-methylenedioxymethamphetamine (ecstasy)induced neurotoxicity in cultured cortical neurons
